Description
Mahacef-Plus Tablet is a combination medication used to treat a variety of bacterial infections. It effectively combats microorganisms, inhibiting their growth and preventing the spread of infection.
Salt Composition
- Cefixime (200mg)
- Ofloxacin (200mg)
How to Use
Take Mahacef-Plus Tablet as prescribed by your healthcare provider. It can be taken with or without food, but should be taken at the same time each day for optimal effectiveness. Swallow the tablet whole; do not chew, crush, or break it. If you miss a dose, take it as soon as you remember, but do not exceed the recommended dose.
Restrictions
Before starting this medication, inform your doctor if you are on any other medications. Pregnant or breastfeeding women should seek medical advice prior to use. Avoid alcohol, as it may enhance drowsiness. While it generally does not affect your ability to drive, avoid driving if you feel sleepy or dizzy. Ensure adequate rest, maintain a healthy diet, and stay hydrated during your treatment. Your doctor may recommend laboratory tests to monitor your response to the medication.
Side Effects
Common side effects include nausea, vomiting, diarrhea, and indigestion. If any side effects worsen, consult your doctor. Seek immediate medical attention if you experience allergic reactions such as rashes, itching, swelling, or difficulty breathing.
Uses of Mahacef-Plus Tablet
- Treatment of bacterial infections
Benefits of Mahacef-Plus Tablet
Mahacef-Plus Tablet combines two antibiotics that work synergistically to combat various bacterial infections. Cefixime halts bacterial growth, while Ofloxacin prevents the reproduction and repair of bacteria, thus curbing infection spread. This medication can address multiple bacterial infections, including those affecting the ears, sinuses, throat, lungs, urinary tract, skin, and soft tissues. Although you may feel better within a few days, it is important to complete the full course of treatment to eliminate all bacteria and prevent resistance.
Marketer
Mankind Pharma Ltd.
